Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer Reply

被引：0
|
作者：
O'Sullivan, Ciara C. [1 ]
Holmes, Eileen [2 ]
Campbell, Christine [2 ]
Bradbury, Ian [2 ]
Zujewski, Jo Anne [1 ]
Gelber, Richard D. [3 ,4 ,5 ,6 ]
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] Frontier Sci, Kingussie, Inverness, Scotland
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 06期
关键词：
ADJUVANT TRASTUZUMAB; SERIES;
D O I：
10.1200/JCO.2015.65.1034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：640 / +
页数：2
相关论文
共 50 条
  • [1] Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer
    Oguz, Arzu
    Keskin, Gul Sema
    Colak, Dilsen
    Altundag, Ozden
    Akcali, Zafer
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 639 - +
  • [2] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    [J]. PLOS ONE, 2019, 14 (06):
  • [3] Development and validation of a prognostic nomogram for early HER2-positive and lymph node-negative breast cancer
    Shi, Qiyun
    Wang, Ju
    Ai, Xiang
    Xuhong, Juncheng
    Ma, Dandan
    Zhang, Yi
    Qi, Xiaowei
    Jiang, Jun
    [J]. GLAND SURGERY, 2021, 10 (07) : 2255 - +
  • [4] Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer
    Sharifi, Marina
    Wisinski, Kari B.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 482 - 492
  • [5] Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer
    Cadoo, Karen A.
    Morris, Patrick G.
    Cowell, Elizabeth P.
    Patil, Sujata
    Hudis, Clifford A.
    McArthur, Heather L.
    [J]. CLINICAL BREAST CANCER, 2016, 16 (06) : 487 - 493
  • [6] Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian, Mathew A.
    Ma, Cynthia X.
    [J]. BREAST DISEASES, 2015, 26 (04): : 285 - 287
  • [7] Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    Tolaney, Sara M.
    Barry, William T.
    Dang, Chau T.
    Yardley, Denise A.
    Moy, Beverly
    Marcom, P. Kelly
    Albain, Kathy S.
    Rugo, Hope S.
    Ellis, Matthew
    Shapira, Iuliana
    Wolff, Antonio C.
    Carey, Lisa A.
    Overmoyer, Beth A.
    Partridge, Ann H.
    Guo, Hao
    Hudis, Clifford A.
    Krop, Ian E.
    Burstein, Harold J.
    Winer, Eric P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02): : 134 - 141
  • [8] Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
    Cochereau, D.
    Cottu, P.
    [J]. ONCOLOGIE, 2015, 17 (04) : 194 - 196
  • [9] Trastuzumab and Chemotherapy May Be Appropriate for Small, Node-Negative, HER2-Positive Breast Cancer In Reply
    Connolly, Roisin M.
    Bardia, Aditya
    [J]. ONCOLOGIST, 2012, 17 (10): : E34 - E34
  • [10] Small Tumor Size and Node-Negative HER2-Positive Breast Cancer: A Step Forward for a Better Treatment? Reply
    Curigliano, Giuseppe
    Bagnardi, Vincenzo
    Fumagalli, Luca
    Rotmensz, Nicole
    Locatelli, Marzia
    Viale, Giuseppe
    Goldhirsch, Aron
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : E258 - E259
12345